Journal
EMBO JOURNAL
Volume 36, Issue 5, Pages 646-663Publisher
WILEY
DOI: 10.15252/embj.201694732
Keywords
14-3-3 proteins; geldanamycin; HSP90 CDC37 complex; sorafenib; vemurafenib
Categories
Funding
- German Research Foundation (DFG) through the Emmy-Noether-and Heisenberg programs [CRC 850, CRC 1140]
- Excellence Initiative of the German Federal and State Governments through FRIAS [EXC 294 BIOSS]
- BMBF [e:Bio 0316184D]
- Danish Natural Sciences Research Council
- Alexander von Humboldt Foundation
Ask authors/readers for more resources
As a central element within the RAS/ERK pathway, the serine/threonine kinase BRAF plays a key role in development and homeostasis and represents the most frequently mutated kinase in tumors. Consequently, it has emerged as an important therapeutic target in various malignancies. Nevertheless, the BRAF activation cycle still raises many mechanistic questions as illustrated by the paradoxical action and side effects of RAF inhibitors. By applying SEC-PCP-SILAC, we analyzed protein-protein interactions of hyperactive BRAF(V600E) and wild-type BRAF (BRAF(WT)). We identified two macromolecular, cytosolic BRAF complexes of distinct molecular composition and phosphorylation status. Hyperactive BRAF(V600E) resides in large complexes of higher molecular mass and activity, while BRAF(WT) is confined to smaller, slightly less active complexes. However, expression of oncogenic K-Ras(G12V), either by itself or in combination with RAF dimer promoting inhibitors, induces the incorporation of BRAF(WT) into large, active complexes, whereas pharmacological inhibition of BRAF(V600E) has the opposite effect. Thus, the quaternary structure of BRAF complexes is shaped by its activation status, the conformation of its kinase domain, and clinically relevant inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available